Cyclic Glycine-Proline vs Metformin
Moderate Research vs FDA Approved
synergistic Mechanism-based · 51% Cyclic Glycine-Proline helps counteract the insulin-disrupting effects of Metformin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Cyclic Glycine-Proline Metformin
Weight 154.17 Da 129.16 Da
Half-life Extended stability (more stable than linear GPE precursor) ~5 hours
Chain 2 amino acids (cyclic) —
Type Cyclic dipeptide (2,5-diketopiperazine) Biguanide (C4H11N5)
Key Benefits
Cyclic Glycine-Proline
01 Neuroprotection and cognitive enhancement
02 IGF-1 optimization
03 Cardiovascular support
04 Metabolic health improvement
05 Blood-brain barrier penetration
06 Convenient oral administration
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Side Effects
Cyclic Glycine-Proline
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
Consult healthcare provider if taking IGF-1 or growth hormone medications
Limited long-term human data available
Not studied in pregnancy
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
Cyclic Glycine-Proline Metformin
Status Moderate Research FDA Approved
References 4 studies 5 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.